Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Unaudited) - USD ($) $ in Thousands	Total	Convertible Preferred Stock	Pfizer License Agreement Convertible Preferred Stock	Common Stock	Additional paid-in capital	Accumulated deficit
Beginning balance at Dec. 31, 2020		$ 21,942
Beginning Balance, Shares at Dec. 31, 2020		22,724,925
Beginning balance at Dec. 31, 2020	$ (15,645)			$ 1	$ 97	$ (15,743)
Beginning Balance, Shares at Dec. 31, 2020				1,289,342
Issuance of Series B convertible preferred stock		$ 152,081	$ 20,000
Issuance of Series B convertible preferred stock, Shares		92,660,103	12,152,145
Vesting of restricted common stock	3				3
Vesting of restricted common stock (Shares)				123,085
Stock-based compensation	2,450				2,450
Net loss	(36,825)					(36,825)
Ending balance at Mar. 31, 2021		$ 194,023
Ending balance (in shares) at Mar. 31, 2021		127,537,173
Ending balance at Mar. 31, 2021	(50,017)			$ 1	2,550	(52,568)
Ending balance (in shares) at Mar. 31, 2021				1,412,427
Beginning balance at Dec. 31, 2020		$ 21,942
Beginning Balance, Shares at Dec. 31, 2020		22,724,925
Beginning balance at Dec. 31, 2020	(15,645)			$ 1	97	(15,743)
Beginning Balance, Shares at Dec. 31, 2020				1,289,342
Net loss	(44,971)
Ending balance at Jun. 30, 2021		$ 194,023
Ending balance (in shares) at Jun. 30, 2021		127,537,173
Ending balance at Jun. 30, 2021	(57,588)			$ 2	3,124	(60,714)
Ending balance (in shares) at Jun. 30, 2021				1,519,007
Beginning balance at Mar. 31, 2021		$ 194,023
Beginning Balance, Shares at Mar. 31, 2021		127,537,173
Beginning balance at Mar. 31, 2021	(50,017)			$ 1	2,550	(52,568)
Beginning Balance, Shares at Mar. 31, 2021				1,412,427
Vesting of restricted common stock	3			$ 1	2
Vesting of restricted common stock (Shares)				106,580
Stock-based compensation	572				572
Net loss	(8,146)					(8,146)
Ending balance at Jun. 30, 2021		$ 194,023
Ending balance (in shares) at Jun. 30, 2021		127,537,173
Ending balance at Jun. 30, 2021	(57,588)			$ 2	3,124	(60,714)
Ending balance (in shares) at Jun. 30, 2021				1,519,007
Beginning balance at Dec. 31, 2021	261,313			$ 32	352,999	(91,718)
Beginning Balance, Shares at Dec. 31, 2021				32,222,881
Stock options exercised	176				176
Stock options exercised (Shares)				51,118
Vesting of restricted common stock	1				1
Vesting of restricted common stock (Shares)				100,908
Stock-based compensation	3,404				3,404
Net loss	(31,380)					(31,380)
Ending balance at Mar. 31, 2022	233,514			$ 32	356,580	(123,098)
Ending balance (in shares) at Mar. 31, 2022				32,374,907
Beginning balance at Dec. 31, 2021	$ 261,313			$ 32	352,999	(91,718)
Beginning Balance, Shares at Dec. 31, 2021				32,222,881
Stock options exercised (Shares)	64,838
Net loss	$ (56,942)
Ending balance at Jun. 30, 2022	211,966			$ 32	360,594	(148,660)
Ending balance (in shares) at Jun. 30, 2022				32,483,883
Beginning balance at Mar. 31, 2022	233,514			$ 32	356,580	(123,098)
Beginning Balance, Shares at Mar. 31, 2022				32,374,907
Stock options exercised	1				1
Stock options exercised (Shares)				13,720
Vesting of restricted common stock (Shares)				95,256
Stock-based compensation	4,013				4,013
Net loss	(25,562)					(25,562)
Ending balance at Jun. 30, 2022	$ 211,966			$ 32	$ 360,594	$ (148,660)
Ending balance (in shares) at Jun. 30, 2022				32,483,883